Navigation Links
Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
Date:2/26/2009

rax. The Company expects to receive at least $150 million from this sale in 2009, with most of the revenue expected in the first quarter. ABthrax is being developed under a contract entered into in 2006 with the Biomedical Advanced Research and Development Authority (BARDA) of the Office of the Assistant Secretary for Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS). Also under the contract, the Company plans to file a Biologics License Application (BLA) with the FDA in the second quarter of 2009. HGS will receive an additional $15 million from the U.S. Government upon FDA licensure of ABthrax.

Albuferon(R): Positive Data Announced for First of Two Phase 3 Trials in Chronic Hepatitis C Patients; Results of Second Phase 3 Trial Expected in March 2009

In December 2008, HGS reported that Albuferon (albinterferon alfa-2b) met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) in ACHIEVE 2/3, the Phase 3 clinical trial of Albuferon in treatment-naive patients with genotypes 2 and 3 chronic hepatitis C. The data showed that the rate of sustained virologic response was comparable for the 900-mcg dose of Albuferon administered every two weeks, vs. the standard 180-mcg dose of peginterferon alfa-2a administered once weekly. Rates of serious adverse events, severe adverse events and discontinuations due to adverse events were also comparable. ACHIEVE 1, the second Albuferon Phase 3 clinical trial, is being conducted in treatment-naive patients with genotype 1 chronic hepatitis C; data are expected in March 2009. Assuming success in Phase 3, HGS expects that global marketing applications will be filed in fall 2009. Albuferon is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.

LymphoStat-B(R): Phase 3 Results Expected in July and November 2009


'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
2. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
3. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
4. Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs
5. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
6. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
7. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
8. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
9. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
10. 2008 Human Research Protection Award Recipients Announced
11. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... TAIPEI , Sept. 1, 2015 ... 2,500 employees, SHL Group has rapidly reached 3,000 ... yet rapid growth in the injectable drug delivery ... A global leader in the design ... SHL offers innovative designs, robust manufacturing capabilities, a ...
(Date:9/1/2015)... Sept. 1, 2015 Pressure BioSciences, Inc. ... in the development and sale of broadly enabling, ... the worldwide life sciences industry, today announced the ... the Company,s PCT Platform could play a significant ... This role is based on PCT,s unique ability ...
(Date:9/1/2015)...  Abbott (NYSE: ABT ) announced today positive one-year ... comparing the safety and effectiveness of Abbott,s fully dissolving ... market-leading, permanent drug eluting stent. The trial was conducted ... and enrolled 400 people with coronary artery disease, the ... be featured at a late-breaking session today at ESC ...
Breaking Medicine Technology:SHL Group Reaches Major Milestone of 3000 Employees 2New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 2New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 3New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 5Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 2Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 3Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 4
... , NEW YORK, November 17 ... biomarkers will help identify and monitor patients at risk,of developing ... are,cared for in prenatal clinics around the world. , ... highly-respected National,Institute of Child and Human Development of the National ...
... , NEW YORK, Nov. 17 ... Street is the first laser hair removal center in New ... system by Cynosure, Inc., a leading developer and manufacturer of ... Elite MPX, which incorporates Cynosure,s patented MultiPlex sequencing technology, is ...
Cached Medicine Technology:New Study Heralds Use of Blood Biomarkers to Predict Preeclampsia 2New Study Heralds Use of Blood Biomarkers to Predict Preeclampsia 3Romeo and Juliette Laser Hair Removal Is First Center in New York City to Own Cynosure's New Elite MPX(TM) Laser System 2
(Date:9/1/2015)... ... September 01, 2015 , ... Negative pressure wound ... a wound to remove exudates, fluid, and infectious materials to prepare the wound ... devices, disposable devices, and canisters, etc.) is projected to expand continuously through 2021. ...
(Date:9/1/2015)... ... September 01, 2015 , ... Plaza OBGYN in Houston, ... Touch® , an innovative vaginal health laser procedure that prevents and resolves dryness ... for atrophic vaginitis, a condition that causes vaginal dryness, pelvic discomfort, painful intercourse ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... has announced that Edge Information Management has been granted continued accreditation ... Credentialing Council (BSCC). , ÔÇťAchieving and maintaining this accreditation takes the ...
(Date:9/1/2015)... MA (PRWEB) , ... September 01, 2015 , ... ... remote real-time monitoring and analysis of pet vital signs and activity, today announced ... is one of the most popular and widely-adopted veterinary hospital Practice Management Software ...
(Date:9/1/2015)... Francisco, Calif. (PRWEB) , ... September 01, 2015 ... ... to corporations, law firms and government entities, announced today that it has hired ... Senior Discovery Consultant. In this capacity, Sanderson will be responsible for establishing ...
Breaking Medicine News(10 mins):Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2
... mediator in the blood that influences immune cell migration ... between the build-up and breakdown of bones in the ... bone, may provide a new target for scientists developing ... and rheumatoid arthritis. , The study comes ...
... WASHINGTON, Feb. 7 As the military deals with ... of Veterans Affairs Eric K. Shinseki reminded Veterans and ... has an extensive array of services to help Veterans ... take advantage of our suicide-prevention program," said Shinseki. "Help ...
... women who got injections report reduced pain and ... first evidence that gene therapy can ease symptoms in ... American and German researchers. , The study included ... interleukin-1 receptor antagonist (IL-1Ra) gene into the women,s affected ...
... CVD ) today announced that it will present at ... 2009 at 3:30 p.m. (ET). Investors may access a ... In order to register and download any necessary software, please ... Princeton, New Jersey, is one of the world,s largest and ...
... World Heart Corporation,("WorldHeart", Nasdaq: WHRT ), ... has appointed John Alexander ("Alex") Martin as,President and CEO. ... the Board of,Directors. Mr. Martin joins WorldHeart from ... Region and Corporate Vice President since,2004. Previously, Alex ...
... the same as supplement available in U.S., study says , , ... and 6 sulfate (CS) appears to slow the worsening and ease ... , The European study, published in the February issue ... CS over two years lost less joint space -- with few ...
Cached Medicine News:Health News:Scientists discover key factor in controlling the breakdown of bone 2Health News:Scientists discover key factor in controlling the breakdown of bone 3Health News:VA Suicide Prevention Hotline Credited with 2,600 'Saves' 2Health News:Gene Therapy May Ease Rheumatoid Arthritis 2Health News:WorldHeart Appoints New President and CEO 2Health News:WorldHeart Appoints New President and CEO 3
RIA kit for the quantitative determination of autoantibodies to thyroid peroxidase (TPO) in serum....
For the quantitative determination of Estradiol (E2) concentration in human serum or plasma....
... Estradiol (E2) concentration in human serum or plasma. ... a phenolic A ring. This steroid hormone ... is the most potent natural Estrogen, produced mainly ... by the adrenal cortex, and the male testes. ...
... (cTnI) has been useful in the differential ... (ED) with chest pain. 18-20 ... levels of sensitive and specific biomarkers, such ... creatine kinase (CK-MB), and myoglobin, are increased ...
Medicine Products: